Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: NNC0113-0987Drug: placebo
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 82
- Registration Number
- NCT01967589
Project to Update the Study of Congenital Haemophilia in Spain
Completed
- Conditions
- Haemophilia ACongenital Bleeding DisorderHaemophilia B
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1157
- Registration Number
- NCT01959555
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7637
- Registration Number
- NCT01959529
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka
Withdrawn
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT01957592
A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid ArthritisInflammation
- Interventions
- Drug: NNC0215-0384Drug: placebo
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT01955603
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-09-27
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 557
- Registration Number
- NCT01952145
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
Phase 1
Completed
- Conditions
- Haemophilia BHaemophilia B With InhibitorsHaemophilia ACongenital Bleeding DisorderHaemophilia A With Inhibitors
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT01949792
GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Behavioral: No treatment givenBehavioral: survey
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1800
- Registration Number
- NCT01950650
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Behavioral: No treatment givenBehavioral: survey
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4000
- Registration Number
- NCT01950637
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- HealthyGrowth Disorder
- Interventions
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01943084
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath